Pliant Therapeutics, Inc.

PLRX

US7291391057

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
11.81 ^USD	-0.59%		-5.67%	-34.79%

Mar. 12	Pliant Therapeutics, Inc. Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis	CI
Mar. 05	RBC Lifts Price Target on Pliant Therapeutics to $54 From $50, Says Bexotegrast Could Have Multi-Billion-Dollar Revenue Opportunity; Outperform, Speculative Risk Kept	MT

Pliant Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023

February 27, 2024 at 04:03 pm EST

Pliant Therapeutics, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 41.11 million compared to USD 35.06 million a year ago. Basic loss per share from continuing operations was USD 0.69 compared to USD 0.72 a year ago.
For the full year, sales was USD 1.58 million compared to USD 9.69 million a year ago. Net loss was USD 161.34 million compared to USD 123.32 million a year ago. Basic loss per share from continuing operations was USD 2.75 compared to USD 2.94 a year ago.

Latest news about Pliant Therapeutics, Inc.

Pliant Therapeutics, Inc. Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis	Mar. 12	CI
RBC Lifts Price Target on Pliant Therapeutics to $54 From $50, Says Bexotegrast Could Have Multi-Billion-Dollar Revenue Opportunity; Outperform, Speculative Risk Kept	Mar. 05	MT
RBC Cuts Price Target on Pliant Therapeutics to $50 From $53, Keeps Outperform, Speculative Risk	Feb. 28	MT
Pliant Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 27	CI
Oppenheimer Adjusts Pliant Therapeutics Price Target to $47 From $49, Maintains Outperform Rating	Feb. 06	MT
Transcript : Pliant Therapeutics, Inc. - Special Call	Feb. 05
HC Wainwright Adjusts Pliant Therapeutics Price Target to $48 From $52, Maintains Buy Rating	Feb. 05	MT
Pliant Therapeutics Reports Interim 'Positive' Safety, Efficacy Data for Potential Liver Disease Drug	Feb. 05	MT
Pliant Therapeutics, Inc. Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis	Feb. 04	CI
Pliant Therapeutics Insider Sold Shares Worth $443,173, According to a Recent SEC Filing	Jan. 19	MT
Top Premarket Decliners	Jan. 11	MT
Transcript : Pliant Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 07:30 AM	Jan. 09
RBC Trims Price Target on Pliant Therapeutics to $53 From $54, Keeps Outperform, Speculative Risk	Nov. 10	MT
Pliant Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Pliant Therapeutics Appoints Chief Regulatory Officer	23-10-16	MT
Pliant Therapeutics, Inc. Appoints S. Mishima Gerhart as Chief Regulatory Officer	23-10-16	CI
HC Wainwright Adjusts Price Target on Pliant Therapeutics to $52 From $50, Maintains Buy Rating	23-09-27	MT
Transcript : Pliant Therapeutics, Inc. - Special Call	23-09-26
Pliant Therapeutics, Inc. Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis	23-09-26	CI
Pliant Therapeutics to Discuss Interim Results Phase 2a Primary Sclerosing Cholangitis Trial Tuesday; Shares Surge Premarket	23-09-26	MT
Pliant Therapeutics to Discuss Interim Results From Phase 2a Primary Sclerosing Cholangitis Trial Tuesday; Shares Surge After-Hours	23-09-25	MT
Pliant Therapeutics, Inc. Appoints Minnie Kuo as Chief Development Officer	23-09-15	CI
Oppenheimer Adjusts Pliant Therapeutics Price Target to $52 From $51, Maintains Outperform Rating	23-08-10	MT
RBC Cuts Price Target on Pliant Therapeutics to $54 From $57, Keeps Outperform Rating, Speculative Risk Qualifier	23-08-10	MT
Earnings Flash (PLRX) PLIANT THERAPEUTICS Reports Q2 Revenue $248,000	23-08-09	MT

Chart Pliant Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Pliant Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing therapies for the treatment of fibrosis and related diseases. Its lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of Î±vÃ6 and Î±vÃ1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). The Company has initiated BEACON-IPF, a Phase 2b trial of bexotegrast in IPF. It has also developed PLN-1474, a small molecule, selective inhibitor of Î±vÃ1 integrin for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis. It has initiated a Phase 1 study for its third clinical program, PLN-101095, a small molecule, dual-selective inhibitor of Î±vÃ8 and Î±vÃ1 integrins, that is being developed for the treatment of solid tumors. The Company has a preclinical program, PLN-101325, targeting muscular dystrophies.

Sector

Pharmaceuticals

Calendar

2024-05-05 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Pliant Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

11.81 USD

Average target price

43 USD

Spread / Average Target

+264.10%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PLIANT THERAPEUTICS, INC.	-34.79%	712M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals